Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Front Cell Dev Biol ; 9: 740267, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34497810

RESUMO

Thyroid cancer ranks second in the incidence rate of endocrine malignant cancer. Thyroid cancer is usually asymptomatic at the initial stage, which makes patients easily miss the early treatment time. Combining genetic testing with imaging can greatly improve the diagnostic efficiency of thyroid cancer. Researchers have discovered many genes related to thyroid cancer. However, the effects of these genes on thyroid cancer are different. We hypothesize that there is a stronger interaction between the core genes that cause thyroid cancer. Based on this hypothesis, we constructed an interaction network of thyroid cancer-related genes. We traversed the network through random walks, and sorted thyroid cancer-related genes through ADNN which is fusion of Adaboost and deep neural network (DNN). In addition, we discovered more thyroid cancer-related genes by ADNN. In order to verify the accuracy of ADNN, we conducted a fivefold cross-validation. ADNN achieved AUC of 0.85 and AUPR of 0.81, which are more accurate than other methods.

2.
Nan Fang Yi Ke Da Xue Xue Bao ; 28(5): 839-42, 2008 May.
Artigo em Chinês | MEDLINE | ID: mdl-18504215

RESUMO

OBJECTIVE: To compare the therapeutic effect of recombinant human brain natriuretic peptide (rhBNP) and nitroglycerin on acute decompensated heart failure (ADHF). METHODS: Fifty ADHF patients were randomly divided into rhBNP group and nitroglycerin group. In all the patients, dyspnea and global clinical status were assessed before and at 30 min, 6 h and 24 h after drug administration, and the volume of fluid intake and urine along with hemodynamic parameters was recorded 24 h after drug administration. In the nitroglycerin group, the patients received an initial nitroglycerin dose of 5 microg/min, with subsequent dose increment of 5 microg/min every 3 to 5 min; the dose was adjusted individually according to the hemodynamics of the patients. The patients in rhBNP group were given rhBNP at the initial dose of 1.5 microg/kg by with an intravenous bolus injection followed by infusion at the rate of 0.0075 microg.kg(-1).min(-1) for 72 h. RESULTS: At 30 min and 6 h after drug administration, the patients in the rhBNP group showed significant greater improvement of dyspnea (P=0.042 and 0.019) and global clinical status (P=0.018 and 0.044) than those in the nitroglycerin group, but 24 h after drug administration, no significant difference was noted between the two groups (P=0.192 and 0.179). Twenty-four hours after drug administration, the mean urine volume was significantly greater in rhBNP group than in nitroglycerin group (1513.8-/+242.9 vs 1341.2-/+239.7 ml, P=0.015), and the ejection fraction increased and pulmonary arterial pressure and systolic blood pressure decreased at greater amplitude in the former group (P=0.001,0.000 and 0.002, respectively). At 72 h, the numbers of premature ventricular contraction and couplets premature beats and onset of paroxysmal ventricular tachycardia were significantly reduced in rhBNP group as compared with the nitroglycerin group (P=0, 0.001 and 0.002, respectively). CONCLUSION: RhBNP promotes urine excretion, decreases pulmonary arterial pressure and increases left ventricular ejection fraction to improve dyspnea and global clinical status and reduce the onset of ventricular arrhythmia in ADHF patients.


Assuntos
Insuficiência Cardíaca/tratamento farmacológico , Peptídeo Natriurético Encefálico/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Pressão Sanguínea/efeitos dos fármacos , Feminino , Insuficiência Cardíaca/patologia , Insuficiência Cardíaca/fisiopatologia , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Peptídeo Natriurético Encefálico/administração & dosagem , Peptídeo Natriurético Encefálico/genética , Doadores de Óxido Nítrico/administração & dosagem , Doadores de Óxido Nítrico/uso terapêutico , Nitroglicerina/administração & dosagem , Nitroglicerina/uso terapêutico , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/uso terapêutico , Resultado do Tratamento
3.
Nan Fang Yi Ke Da Xue Xue Bao ; 28(4): 542-4, 2008 Apr.
Artigo em Chinês | MEDLINE | ID: mdl-18495585

RESUMO

OBJECTIVE: To investigate the effects of ultrasound mediated microbubble destruction on capillary permeability in rat skeletal muscles. METHODS: Eighteen SD rats were randomized into 3 groups, namely the Evans blue (EB) group, EB+ultrasound (E+U) group and EB+microbubble+ultrasound (U+E+M) group with corresponding treatments, using EB injected into the carotid artery as the indicator for capillary permeability. The microbubbles were injected through the carotid artery with fixed ultrasound parameters. The spillover of EB was estimated under fluorescence microscope according to the visual staining scores. The contents of EB in the skeletal muscles were calculated according to the standard curve and spectrophotometry. RESULTS: EB spillover was observed around the capillaries in E+U+M group, which had a significantly higher visual score than EB group and E+U group (0 and 0-1, respectively, P<0.05). The EB content was 51.57-/+3.89 microg/g in E+U+M group, also significantly higher than those in EB group (28.99-/+4.67 microg/g) and E+U group (30.99-/+4.11 microg/g) (P<0.05). CONCLUSION: Exposure to both ultrasound and microbubble contrast agents results in increased capillary permeability of rat skeletal muscles, which might be an important mechanisms for gene delivery enhancement by ultrasound contrast agents.


Assuntos
Permeabilidade Capilar/fisiologia , Microbolhas , Músculo Esquelético/irrigação sanguínea , Ultrassom , Animais , Corantes/administração & dosagem , Corantes/farmacocinética , Meios de Contraste/administração & dosagem , Azul Evans/administração & dosagem , Azul Evans/farmacocinética , Feminino , Masculino , Microscopia de Fluorescência , Músculo Esquelético/metabolismo , Distribuição Aleatória , Ratos , Ratos Sprague-Dawley , Espectrofotometria
4.
Zhonghua Yi Xue Za Zhi ; 87(16): 1136-8, 2007 Apr 24.
Artigo em Chinês | MEDLINE | ID: mdl-17673000

RESUMO

OBJECTIVE: To investigate the optimal atrioventricular delay (AVD) in using dual-chamber pacemaker. METHODS: Thirty patients with atrioventricular conduction block, aged 62 +/- 12, implanted for were implanted with DDD pacemakers. Program controller was used to program the AVD. Two-dimensional echocardiography was used to measure the hemodynamic parameters: cardiac output (CO), cardiac output index (CI), stroke volume (SV), left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESd), left ventricular end-diastolic diameter (LVEDd), peak systolic velocity (Vs), and peak systolic time of the basic segment at inter-ventricular septum and left ventricular under the pattern of tissue velocity imaging at different values of AVD. For each patient, the AVD was prolonged to 250 ms stepwise by 30 ms starting from 100 ms. RESULTS: Cardiac function changed with different AVD. When the AVD was 160 ms, the maximal values were reached for CO (5.5 L/min+/-1.1 L/min, P<0.05), CI (3.5 Lxmin(-1)xm(-2)+/-0.8 Lxmin(-1)xm(-2), P<0.05), SV (78 ml+/-13 ml, P<0.05), LVEF (67%+/-7%, P<0.05), LVEDd (121 mm+/-29 mm, P<0.05), and Vs. LVESd reached its minimal value (37 mm+/-16 mm, P<0.05) and the Vs values of different ventricular walls reached the minimal too (all P<0.05). CONCLUSION: When the optimal AVD is selected the cardiac function can be significantly improved. Tissue Doppler echocardiography is useful in evaluating cardiac function and determining the optimal AVD.


Assuntos
Estimulação Cardíaca Artificial , Bloqueio Cardíaco/fisiopatologia , Bloqueio Cardíaco/terapia , Adulto , Idoso , Idoso de 80 Anos ou mais , Ecocardiografia Doppler , Feminino , Seguimentos , Bloqueio Cardíaco/diagnóstico por imagem , Humanos , Masculino , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...